Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ling Peng, Kui Xiao, Jian Cui, Xiang-Hua Ye, Yong-Chang Zhang, Li Mao, Giovanni Selvaggi, Jennifer Yen & Justin Stebbing. (2021) Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC. OncoTargets and Therapy 14, pages 3409-3415.
Read now
Read now
Articles from other publishers (23)
Junko Tanizaki & Hidetoshi Hayashi. (2024) Unraveling Pseudo Kidney Injury: The Significance of Understanding Our “MATE” in Molecular-Targeted Therapies. Journal of Thoracic Oncology 19:1, pages 15-17.
Crossref
Crossref
Laura Fabbri, Alessandro Di Federico, Martina Astore, Virginia Marchiori, Agnese Rejtano, Renata Seminerio, Francesco Gelsomino & Andrea De Giglio. (2023) From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). Diagnostics 14:1, pages 48.
Crossref
Crossref
Bole Li, Shan Liu, Honglei Feng, Chunshuang Du, Liman Wei, Jie Zhang, Guangwei Jia & Chunnuan Wu. (2023) Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib. Frontiers in Pharmacology 14.
Crossref
Crossref
Pelinsu Korucu Aktas, Ipek Baysal, Samiye Yabanoglu-Ciftci & Betul Arica. (2023) Development and In Vitro Evaluation of Crizotinib-Loaded Lipid–Polymer Hybrid Nanoparticles Using Box–Behnken Design in Non-small Cell Lung Cancer. AAPS PharmSciTech 24:7.
Crossref
Crossref
Neeraj Gupta, Michael J. Hanley, Robert J. Griffin, Pingkuan Zhang, Karthik Venkatakrishnan & Vikram Sinha. (2023) Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor. Clinical Pharmacokinetics 62:8, pages 1063-1079.
Crossref
Crossref
Ya-nan Liu, Jie Chen, Jing Wang, Qingqing Li, Guo-xin Hu, Jian-ping Cai, Guanyang Lin & Ren-ai Xu. (2023) Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism. Archives of Toxicology 97:8, pages 2133-2142.
Crossref
Crossref
Mrunal Pradeep Desai, Prajakta Harish Patil, Sai Krishna Anand Vullendula, Sumit Birangal, G. Gautham Shenoy, Mahadev Rao, Swapnil Jayant Dengale, Krishnamurthy Bhat & Jagadish Puralae Channabasavaiah. (2023) Molecular Insights into the Mechanism of Modulatory Effects of Proton Pump Inhibitors
on P-glycoprotein Mediated Drug Transport of Palbociclib and Ribociclib. Current Drug Metabolism 24:6, pages 458-465.
Crossref
Crossref
Quentin Dominique Thomas, Nelly Firmin, Litaty Mbatchi, Alexandre Evrard, Xavier Quantin & Fanny Leenhardt. (2023) Combining Three Tyrosine Kinase Inhibitors: Drug Monitoring Is the Key. International Journal of Molecular Sciences 24:6, pages 5518.
Crossref
Crossref
Sumit Kumar Saha, Amita Joshi, Romi Singh, Suvamay Jana & Kiran Dubey. (2023) An investigation into solubility and dissolution improvement of alectinib hydrochloride as a third-generation amorphous solid dispersion. Journal of Drug Delivery Science and Technology 81, pages 104259.
Crossref
Crossref
Tsuyoshi Kiyota, Yuki Ando & Atsushi Kambayashi. (2022)
Dynamic Changes in Gastrointestinal Fluid Characteristics after Food Ingestion Are Important for Quantitatively Predicting the
In Vivo
Performance of Oral Solid Dosage Forms in Humans in the Fed State
. Molecular Pharmaceutics 20:1, pages 357-369.
Crossref
Crossref
David Malnoë, Olivier Fardel & Pascal Le Corre. (2022) Involvement of Transporters in Intestinal Drug–Drug Interactions of Oral Targeted Anticancer Drugs Assessed by Changes in Drug Absorption Time. Pharmaceutics 14:11, pages 2493.
Crossref
Crossref
Ashwin Kamath, Suresh Kumar Srinivasamurthy, Mukta N. Chowta, Sheetal D. Ullal, Youssef Daali & Uppugunduri S. Chakradhara Rao. (2022) Role of Drug Transporters in Elucidating Inter-Individual Variability in Pediatric Chemotherapy-Related Toxicities and Response. Pharmaceuticals 15:8, pages 990.
Crossref
Crossref
Zhen Li, Fang Liu, Shuang Wu, Shi Ding, Ye Chen & Ju Liu. (2022) Research Progress on the Drug Resistance of ALK Kinase Inhibitors. Current Medicinal Chemistry 29:14, pages 2456-2475.
Crossref
Crossref
Stefano Fogli, Fabrizio Tabbò, Annalisa Capuano, Marzia Del Re, Francesco Passiglia, Federico Cucchiara, Cristina Scavone, Veronica Gori, Silvia Novello, Manuela Schmidinger & Romano Danesi. (2022) The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences. Critical Reviews in Oncology/Hematology 172, pages 103602.
Crossref
Crossref
Iago Dillion Lima CavalcantiIago Dillion Lima Cavalcanti. 2022. Chemotherapy Protocols and Infusion Sequence. Chemotherapy Protocols and Infusion Sequence
1
25
.
Christos Fountzilas, Alex Adjei, Mateusz Opyrchal, Rachel Evans, Mohammad Ghasemi, Kristopher Attwood, Adrienne Groman, Wiam Bshara, Andrew Goey, John Wilton, Wen Wee Ma & Renuka Iyer. (2021)
A phase I study of the
anaplastic lymphoma kinase
inhibitor ceritinib in combination with
gemcitabine‐based
chemotherapy in patients with advanced solid tumors
. International Journal of Cancer 149:12, pages 2063-2074.
Crossref
Crossref
Jiaolong Wang, Chunlong Sun, Min Ji, Baoqin Wang, Peng Wang, Gaoxin Zhou, Bin Dong, Wen Du, Li Huang, Hongguo Wang & Lili Ren. (2021) Design, synthesis and application of near-infrared fluorescence probe IR-780-Crizotinib in detection of ALK positive tumors. Protein Expression and Purification 187, pages 105952.
Crossref
Crossref
Huiping Xu, Melissa T. O'Gorman, Sunil Nepal, Lee P. James, Katherine Ginman & Yazdi K. Pithavala. (2021) Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. Clinical Pharmacology in Drug Development 10:11, pages 1395-1404.
Crossref
Crossref
Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, Michel Tod & Sylvain Goutelle. (2021) Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy 65:9.
Crossref
Crossref
Gayathri Baburaj, Levin Thomas & Mahadev Rao. (2021) Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. Archives of Medical Research 52:3, pages 261-269.
Crossref
Crossref
Go Makimoto, Keita Kawakado, Masamoto Nakanishi, Tomoki Tamura & Shoichi Kuyama. (2021) Successful Treatment with Lorlatinib after the Development of Alectinib-Induced Liver Damage in ALK-Positive Non-Small-Cell Lung Cancer: A Case Report. Case Reports in Oncology 14:1, pages 197-201.
Crossref
Crossref
Mohammed Muqtader Ahmed, Farhat Fatima, Md. Khalid Anwer, Mohammed F. Aldawsari, Yasser Saud M. Alsaidan, Suliman Abdulaziz Alfaiz, Anzarul Haque, Alanazi AZ & Khalid Alhazzani. (2020) Development and characterization of Brigatinib loaded solid lipid nanoparticles: In-vitro cytotoxicity against human carcinoma A549 lung cell lines. Chemistry and Physics of Lipids 233, pages 105003.
Crossref
Crossref
Jukka Hakkola, Janne Hukkanen, Miia Turpeinen & Olavi Pelkonen. (2020) Inhibition and induction of CYP enzymes in humans: an update. Archives of Toxicology 94:11, pages 3671-3722.
Crossref
Crossref